Literature DB >> 35087365

When Is Sentinel Node Biopsy Indicated in High-Risk Ductal Carcinoma in situ? Four Hundred Sixty-Eight Cases from Three Institutions.

Tomás Cortadellas1, Paula Argacha1, Juan Acosta1, Judith Jurado1, Ricardo Peiró1, Margarita Gomez1, Xavier Gonzalez-Farré1, Milagros Martinez1, Miguel Luna2, Vicente Peg3, Antonio Gil-Moreno3, Manel Xiberta1.   

Abstract

INTRODUCTION: Sentinel lymph node biopsy (SLNB) in ductal carcinoma in situ (DCIS) is not indicated. However, in certain cases (size >3 cm, high grade, mass effect on mammography, or palpable mass), it may be possible to find incidental invasive carcinoma (IC) that requires an SLNB. We studied the correlation of the aforesaid factors with the probability of finding IC in the surgical specimen.
METHODS: Data was collected from 3 different institutions between 2010 and 2016, recording characteristics such as, but not limited to: high grade, size >3 cm, mass effect on mammography, and palpable mass.
RESULTS: On the whole, 468 "high-risk" DCIS cases were identified, 139 (29%) of which had IC. When the DCIS was high grade or the size was >3 cm, there was no significant difference in the probability of finding IC in the surgical specimen (OR = 1.13; 95% CI 0.84-1.51; OR = 1.2; 95% CI 0.85-1.40). Nevertheless, when a high grade and size (>3 cm) were combined, IC was more likely to exist (72.7 vs. 27.3%; p = 0.001). In addition, mass effect and palpation were independently associated with a significantly greater degree of IC (OR = 12.76; 95% CI 6.93-23.52).
CONCLUSIONS: The results suggest that high-grade DCIS or DCIS with a size >3 cm, independently, does not require SLNB. Nonetheless, in the event that both factors are found in the same case, SLNB may be indicated. Additionally, SLNB is advisable for DCIS cases that are palpable or show a mass effect on mammography.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Ductal carcinoma in situ; Sentinel node; Type of surgery in situ

Year:  2021        PMID: 35087365      PMCID: PMC8739945          DOI: 10.1159/000514849

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  28 in total

Review 1.  Clinical role of sentinel-lymph-node biopsy in breast cancer.

Authors:  Mohammed R S Keshtgar; Peter J Ell
Journal:  Lancet Oncol       Date:  2002-02       Impact factor: 41.316

2.  Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.

Authors:  Meagan E Brennan; Robin M Turner; Stefano Ciatto; M Luke Marinovich; James R French; Petra Macaskill; Nehmat Houssami
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

3.  Lymph node metastasis from ductal carcinoma in situ with microinvasion.

Authors:  J Zavotsky; N Hansen; M B Brennan; R R Turner; A E Giuliano
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

4.  The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.

Authors:  L N Broekhuizen; J H Wijsman; J L Peterse; E J Th Rutgers
Journal:  Eur J Surg Oncol       Date:  2006-03-29       Impact factor: 4.424

5.  The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.

Authors:  Ellie J Coromilas; Jason D Wright; Yongmei Huang; Sheldon Feldman; Alfred I Neugut; Ling Chen; Dawn L Hershman
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

6.  The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up.

Authors:  Jonathan F Lara; Steven M Young; Rowena E Velilla; Elissa J Santoro; Sandra F Templeton
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

Review 7.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.

Authors:  Beth A Virnig; Todd M Tuttle; Tatyana Shamliyan; Robert L Kane
Journal:  J Natl Cancer Inst       Date:  2010-01-13       Impact factor: 13.506

8.  Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Gary H Lyman; Mark R Somerfield; Linda D Bosserman; Cheryl L Perkins; Donald L Weaver; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2016-12-12       Impact factor: 44.544

9.  DCIS and axillary nodal evaluation: compliance with national guidelines.

Authors:  Katrina B Mitchell; Heather Lin; Yu Shen; Alfred Colfry; Henry Kuerer; Simona F Shaitelman; Gildy V Babiera; Isabelle Bedrosian
Journal:  BMC Surg       Date:  2017-02-07       Impact factor: 2.102

10.  Associations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ.

Authors:  Brigid K Killelea; Jessica B Long; Weixiong Dang; Sarah S Mougalian; Suzanne B Evans; Cary P Gross; Shi-Yi Wang
Journal:  Ann Surg Oncol       Date:  2018-03-07       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.